The U.K.'s cost-effectiveness watchdog has turned away Afinitor for breast cancer. The Novartis drug doesn't offer enough value for the money, the National Institute for Health and Clinical Excellence says.
How is a generic drug's label different from the drug itself? That was one of the many questions posed yesterday as the generics-liability case had its Supreme Court airing.
Lipitor as a loss leader? That's the approach Wegmans' pharmacies are taking. As the Philadelphia Inquirer reports, the grocery store chain offers generic versions of Lipitor for free, as a way to bring in new pharmacy customers. And the promotion must be successful--Wegmans just extended it through the end of this year.
Suffering Big Pharma well knows that primary-care drug spending slumped in the U.S. last year. That's the patent cliff at work. But now, there's a number for that pain: Spending on mass-market meds dropped 1.5% in 2012.
Given all of the lousy earnings reports and patent cliff talk, one might have expected last year to be the biggest ever for getting new generic drugs into the U.S. market. One would be wrong.
Lundbeck has another chance to crow this week, now that its once-monthly version of Abilify has FDA approval. The agency nod comes fast on the heels of another, for the Danish drugmaker's alcohol addiction drug Selincro. This double victory opens the way for Lundbeck to transform turnaround promises into actual sales.
The U.K.-based company had petitioned the agency to block the copycat versions on packaging grounds.
It was particularly good news today when a federal appeals court upheld the patent for antipsychotic Seroquel XR, one of the key drugs AstraZeneca continues to bank on.
Where would Sanofi be without Lantus? The diabetes drug just keeps on churning up sales growth, quarter after quarter. In the fourth quarter, Lantus products grew by more than 22% to €1.33 billion. For the full year, the drug racked up almost €5 billion.
Forest Laboratories is in dire need of a Bloody Mary for its still-severe Lexapro hangover. The U.S.-based drugmaker fell short of low expectations for the third quarter, thanks to a 41% drop in sales, largely because of generic competition for the blockbuster antidepressant. And the company ratcheted back predictions for its full-year results.